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Abstract: Umbilical cord blood (CB) has become, since its first successful use more than two 
decades ago, an increasingly important source of blood stem cells. In this light, an overview 
of current usage of CB in the field of unrelated hematopoietic blood stem cell transplantation 
(HSCT) is given. The three main sources of hematopoietic stem cells: bone marrow (BM), 
peripheral blood stem cells (PBSC), and cord blood (CB) are compared as regards their   current 
quantitative usage in HSCT. A cost analysis of the named three hematopoietic blood stem cell 
(HSC) sources, taking into account various factors, is undertaken. The health economical 
  comparison shows significant differences between CB on the one side, and BM and PBSC on 
the other. The consequences for the public health side and propositions for a possible health care 
policy, especially regarding future resource allocation towards the different choices for HSCT 
products, are discussed. An outlook on the possible future usage of BM, PBSC, and CB and its 
implications on health systems, donor registries, and CB banks is given.
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Introduction
Umbilical cord blood (CB) has become, since its first successful use more than two 
decades ago, an increasingly important source of blood stem cells. Especially for rare 
Human Leukocyte Antigen (HLA) types (which are often found in non-Caucasian 
patients), it has frequently become the “last resource” because of the possibility of a 
higher mismatch due to the relative immaturity of its blood stem cells, compared to 
those from adult donors derived from bone marrow or apheresis. Today, some 25% 
of all hematopoietic blood stem cell (HSC) donations worldwide are performed with 
umbilical cord blood. Worldwide, there are at present over half a million cord blood 
units (CBUs) stored in public cord blood banks (CBBs). Nearly 4000 CBUs are pro-
vided annually and over 21000 CBUs have been provided to date.1
At first sight, the widespread use of CB seems to be a complete success story. 
This might be at least partially the case from a medical point of view, in particular 
regarding the use of CB in cases where no matching adult stem cell donor is available, 
as is frequently the case with racial or ethnic minorities or with children coming from 
a multi-racial background. However, as the statistics in Table 1 show, up to now only a 
small fraction of all stored CBUs have been used. Does this fact have an impact on the 
long-term financing of cord blood banking? Have resources been allocated efficiently 
in the past years? To give an objective answer to these questions, the author has tried to 
calculate the costs of worldwide cord blood banking, as well as to compare the latter 
with the costs of unrelated adult blood stem cell transplantation, with the two stem ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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cell sources: bone marrow (BM) and peripheral blood stem 
cells (PBSC).
Material and methods
For this paper, information available to the public and own 
organizational data were compiled by the author. A health 
economic analysis was undertaken through the combination 
of general statistical data and past product and process-
specific cost analyses performed by other authors.
Specificities of cord blood  
as a stem cell source
The qualities of CB show quite a number of medical as well 
as logistical advantages, with its rapid availability being one 
of the most crucial. Due to the relative immaturity of CB stem 
cells, a higher degree of mismatching is tolerable in transplan-
tation compared to HSC derived from adult donation.
On the other hand, the limited number of cells a CBU 
contains is one of the most important factors limiting its use 
with infants and adults with a body weight of below 50 kg. 
The technique of double cord transplantation is currently the 
prevailing method to overcome this limitation.
One factor which has escaped notion, probably because 
the transplant community is not aware of it, is the fact that a 
large portion of CB transplantations are performed urgently. 
The advantage of the rapid availability of CBUs is in fact 
a burden for the coordination centers (ie, donor registries), 
insofar as the usual, easier to schedule work of   coordination 
of an unrelated adult stem cell donation has to be put back 
in favor of the urgent organization of a CB donation. This 
fact, known to the author from personal experience as well 
as through discussions with colleagues, has not yet been 
objectified to our knowledge and remains to be quantitatively 
analyzed in the future.
Recent research has shown that in reality, the most often 
demanded CBUs are those with a popular HLA type and a 
high cell count.2 The resulting depletion of a CBB’s inventory 
can only be overcome by a disproportionately high addition 
of new CBUs to such a CBB, to maintain its attractiveness. 
The long-term effects of this phenomenon remain equally 
to be analyzed.
Political environment and international development 
of cord blood banking
In the year 2005, cord blood gained increased attention as 
public bodies worldwide decided to support cord blood 
banking financially, in order to increase the relevant national 
CB inventories. Two examples illustrate this vividly: in the 
United States, the “Stem Cell Therapeutic and Research 
Act of 2005” came into effect in December 2005. The US 
  Congress granted 79 million US dollars (USD) for the 
  development of a US public CB banking system. The goal 
was “…to assist in the collection and maintenance of 150,000 
new units of high-quality cord blood to be made available 
for transplantation…” (Figure 1).3
In Switzerland, the Swiss Foundation Blood stem cells 
(SBSC) decided at the same time to expand the size of the 
national public CBB system, from 1000 to a target inven-
tory of 4000 CBUs. The majority of costs (500,000 to 
900,000 Swiss Francs per year) were to be covered by the 
Foundation.4
In other countries, similar efforts had been undertaken to 
expand the relevant sizes of national public CB inventories, 
due to the rising demand for HSC, especially for ethnic 
minorities. This demand was perceived not to be adequately 
covered by the then existing adult unrelated donor registries. 
In certain countries, the results of such programs have been 
impressive, as Table 2 shows.
Comparison of cord blood against 
unrelated adult stem cell donation
At a time when previously formulated goals regarding inven-
tory size are about to be reached, and with a possible new 
worldwide financial crisis looming, an objective cost-benefit 
analysis seems to be needed.
Before such a comparison is performed, it is necessary to look 
at the development of unrelated adult stem cell donation, which 
has shown an equally impressive growth in the past decade: By 
Table 1 Worldwide development of cord blood banking
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 Cum.
CBUs available 44,000 70,000 105,000 136,000 181,000 229,000 256,000 292,000 406,000 452,000 537,000
CBUs provided 462 508 691 848 1,467 1,740 2,336 2,671 3,393 3,522 3,749 21,387
Percentage 1.05% 0.73% 0.66% 0.62% 0.81% 0.76% 0.91% 0.91% 0.84% 0.78% 0.70% 3.98%
Note: Data sourced from the World Marrow Donor Association (WMDA).1
Abbreviations: CBUs, cord blood units; Cum, cumulative.ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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the end of 2009, more than 16 million donors have been registered 
worldwide, with an annual rate of donations exceeding 11,000 
and almost 90,000 donations having been performed since 1997 
(Figure 2). The exact numbers are shown in Table 3.
The comparison shows amongst others that in the year 2009, 
roughly one quarter of HSC procurements (3,749 out of 15,356) 
were being realized with cord blood as the stem cell source. 
Regarding the “Return of inventory” (ROI) in 2009, cord blood 
was, with 3,749 (0.7%) CBUs provided out of 537,000 banked, 
ten times more effective as unrelated adult stem cell donation 
(11,607 donations (0.07%) out of a worldwide donor population 
of 16.4 million donors). This is probably due to the fact that 
matching criteria are not as strict with cord blood as they are 
with adult stem cell donors; in addition, with CB often used 
as a rescue treatment of second choice, transplant physicians 
seem to be willing to accept more incompatibilities out of the 
available stock of CBUs in such a situation.
In 13 years (1997–2009), 88,422 donations (45,673 PBSC 
plus 42,749 BM) have been performed, with PBSC recently 
becoming clearly the major form of donation (PBSC: 
8,162/70.3% in 2009 versus 3,445/29.7% for BM). From 
1999–2009, a total of 21,387 CBUs have been procured, 
which makes up for a cumulated ROI of nearly 4%. The 
worldwide CBU ROI in 2009 was 0.7% (4,739 out of a total 
of 537,000 CBUs).
Prima vista, these figures seem encouraging. Before a 
health economic comparison can be performed, it is   necessary 
to have a general overview of the costs of production and 
maintenance of the different stem cell sources.
Available product-specific cost 
calculations
Health economic data on the costs of different stem cell 
sources are scarce and heterogeneous, like in many other 
areas of health economy. In our analysis, we used organi-
zational data from the World Marrow Donor Association 
(WMDA), Bone Marrow Donors Worldwide (BMDW), 
and the Swiss Foundation Blood stem cells (SBSC), as well 
as three scientific publications: for cord blood, the works of 
Sirchia and colleagues7 and Howard and colleagues;8 and for 
adult stem cell donors, information from the publication of 
Kollman and colleagues.9
Sirchia et al7 calculate, in their models (comparing differ-
ent CBB types, ranging from 1,500 to 10,000 CBUs inventory 
size), costs of between 11,602 and 15,061 USD per released 
CBU, with the lowest price reached by the model of one big 
CBB with an inventory of 10,000 CBUs. Their pricing is 
based on an assumption of an ROI of 2.8%, which is four 
times higher than that actually achieved.
Howard et al8 compared different scenarios based upon 
different target sizes of a national public CB inventory. Their 
calculations varied also according to total inventory size and 
ranged between a 15,336 USD (50,000 CBU inventory) and 
a 92,675 USD (300,000 CBU inventory) break-even fee per 
CBU. The details of their calculations, including a modifica-
tion (in italics) which will be later explained in this paper, 
can be seen in Table 4.
Kollman et al9 used for their cost estimations, the data 
of the US National Marrow Donor Program (NMDP). They 
came to total costs for the recruitment of a new donor of 
Table 2 Worldwide comparison of public cord blood banking, 
relative to country population
Country Population Factor CBUs  
banked
Population/ 
CBU
Switzerland  7,604,467 2,750 2,765
Germany 82,329,758 10.8 23,502 3,503
United States 307,212,123 40.4 172,614 1,780
Australia 21,262,641 2.8 22,258 955
France 64,420,073 8.5 8,807 7,315
Italy 58,126,212 7.6 20,463 2,841
Belgium 10,414,336 1.4 14,057 741
United Kingdom 61,113,205 8.0 11,217 5,448
Netherlands 16,715,999 2.2 2,841 5,884
Spain 40,525,002 5.3 44,402 913
Notes:  CBU  data  sourced  from  Bone  Marrow  Donors  Worldwide  (BMDW).5 
Population statistics sourced from the U.S. Census Bureau.6 Factor refers to the 
relation of the respective population in relation to the Swiss population, where 
factor for Switzerland is 1.
Abbreviation: CBUs, cord blood units.
Table 3 Worldwide development of unrelated adult stem cell donation
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 Cum.
Donors (× 000) 4,000 5,600 6,300 6,900 7,500 8,200 9,000 9,900 10,700 11,800 13,200 14,600 16,400
BM 3,082 3,552 3,700 3,515 3,238 3,392 3,187 3,133 3,125 3,002 3,157 3,221 3,445 42,749
PBSC 155 282 653 1,127 1,679 2,485 3,198 4,133 4,796 5,416 6,327 7,260 8,162 45,673
Total donations 3,237 3,834 4,353 4,642 4,917 5,877 6,385 7,266 7,921 8,418 9,484 10,481 11,607 88,422
Percentage 0.08% 0.07% 0.07% 0.07% 0.07% 0.07% 0.07% 0.07% 0.07% 0.07% 0.07% 0.07% 0.07% 0.54%
Note: Data sourced from the World Marrow Donor Association (WMDA).1
Abbreviations: BM, bone marrow; PBSC, peripheral blood stem cells; Cum, cumulative.ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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between 113 USD for white persons, and 141 USD for 
non-Caucasian volunteers, based on different recruitment 
fees for donor centers.
Prices (fees) per stem cell product
The above organizational data are fees incurred on the pro-
curement of different stem cell products, and vary between 
those products as well as internationally, between different 
national registries and donor organizations.
Tables 5 (cord blood) and 6 (unrelated adult stem cell 
donation) show the individual prices per procured stem cell 
product. For the sake of simplicity, a rounded average price, 
comprising the procurement fees of the most important donor 
registries, was calculated per world region. In multiplying the 
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individual product prices by the actually delivered products 
(2009 data), total costs have been calculated, which were 
then converted to a weighted average price-per-unit (PPU). 
The calculation shows a difference between the mean prices 
of cord blood and adult stem cell products of 21,486 USD 
(adult) and 27,579 USD (cord blood), or 28.4%. Compared 
to the overall costs of a HSTC transplantation of 200,000 
USD,10 this price differential seems to be acceptable.
Results
Calculation of health care  
system related costs
We undertook the attempt to make a calculation of the costs 
of stem cell products on a global scale. The goal of this 
approach was to have an overall image of worldwide costs 
of stem cell products, as well as comparing CB as well as 
BM and PBSC against each other. The method used was 
the multiplication of available products (CBUs banked vs 
Registered adult donors) by the average costs per product, 
along with the costs of provided products (provided CBUs vs 
BM/PBSC) multiplied by the cumulated total number. This 
resulted in a price-per-product (PPP) which was calculated by 
the division of total costs by the number of delivered products. 
In contrast to this system-based approach (all costs incurred 
by the same health system,) a theoretical institution-based 
approach was used, in which the costs for delivered products 
were regarded as profits, which were subtracted from the total 
inventory build-up costs. The resulting individual price was 
named PPP2.
Four models were used to determine the total prices 
incurred by the health systems for the use of cord blood, 
using the publications of Sirchia et al and Howard et al.7,8 
For each publication, an optimistic (“A”) and a realistic 
(“B”) approach was defined, resulting in different prices-
per-product. In the case of Sirchia et al7 the optimistic 
approaches consisted of using Sirchia’s model of one single 
CBB (10,000 CBU’s), together with the original assumption 
of a ROI of 2.8%. This approach came to a price of 11,602 
USD/CBU. In using a different model, we applied the actual 
worldwide annual CBU ROI of 0.7% to the original calcula-
tion, which resulted in a four-fold increase of the original 
price, leading to costs of 46,408 USD/CBU.
With regard to the calculations of Howard et al8 we used 
on the one hand Howard’s model closest to the actual ROI 
(inventory of 100,000 CBUs, yearly usage of 643 CBUs), 
which had the original calculation of 31,107 USD/CBU. Our 
alternative approach consisted of a modification of the   Howard 
et al model with the biggest inventory size (300,000 CBU) 
which we deemed to be close to the actual worldwide number 
(537,000 CBU). We modified it by using a yearly usage rate of 
2,100 CBUs (0.7% of 300,000), with the respective correction 
of price (“CB fee”) being 29,568 USD/CBU.
The same method was applied for adult stem cell donors, 
using the data from Kollman et al.9 Under the assumption that 
Table 5 Price calculation of provided cord blood products
Region Price  
(USD)
Products 
provided
Total costs 
(USD)
PPU 
(USD)
Americas 34,200 1,702 58,208,400
Europe 24,300 815 19,804,500
Asia-Pacific 20,600 1,232 25,379,200
Grand Total 3,749 103,392,100 27,579
Notes: 2009 data sourced from Bone Marrow Donors Worldwide (BMDW),5 the 
World Marrow Donor Association (WMDA),1 and Swiss Foundation Blood stem 
cell (SBSC) internal data.
Abbreviation: PPU, price-per-unit.
Table 6 Price calculation of procured adult stem cell products
Region Price  
(USD)
Products 
provided
Total costs 
(USD)
PPU  
(USD)
Americas 27,600 2,767 76,369,200
Europe 18,570 6,259 116,231,160
Asia 22,000 2,581 56,782,000
Total 11,607 249,382,360 21,486
Notes: 2009 data sourced from Bone Marrow Donors Worldwide (BMDW),5 the 
World Marrow Donor Association (WMDA),1 and Swiss Foundation Blood stem 
cell (SBSC) internal data.
Abbreviation: PPU, price-per-unit.
Table 4 Price calculation of cord blood related to inventory size
Cord inventory 50,000 100,000 150,000 200,000 300,000 300,000
Cord blood transplants (T) 617 643 655 662 670 2100
Annual cord collection (U)  6,234 11,287 16,310 21,324 31,340 31,340
Costs (USD millions)
Annual bank costs (C)  10 17 25 32 47 47
Direct treatment costs (cTN)  136 142 144 146 147 147
Start-up costs (C0)  0 100 200 300 500 500
Total costs (TC)  146 162 175 187 210 210
Break-even per cord fee (f)  15,336 31,107 46,613 62,014 92,675 29,568
Notes: Calculations based on the publication of Howard et al.8 Italics in the final column are modified data from the original table taking into account transplantation rates 
according to current data (0.7% ROI).ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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other international registries would have higher registration 
costs than the NMDP data used by Kollman,9 we applied the 
higher price (141 USD, for non-Caucasians), even   knowing 
that the majority of registered stem cell donors would 
be   Caucasians. In the second model (“B”), we added main-
tenance costs of 3 USD per donor per year, assuming that the 
average donor would remain in a registry for 20 years; which 
lead to a rounded overall price of 200 USD per unrelated 
adult stem cell donor. In a third model, a “production price” 
for HSC (USD 7100 per donation) was added to the medium 
donation fee calculated above (USD 21,486), using data from 
Smith et al,11 with the calculation of a weighted medium price 
of USD 7100 accounting for the repartition of the two different 
adult stem cell sources to date (45,673 PBSC against 42,749 
BM donations). In the system-based approach, all costs were 
added, whereas in the institution-based approach, fees were 
subtracted from registration plus production costs.
The multiplication of registration and procurement 
costs over the time period 1999–2009, lead to total costs 
for cord blood of between 6.8 and 25.5 billion USD in 
the health system-based approach. When divided per pro-
vided product, unit costs of 318,890 and 1.19 million USD 
per product (CBU) result. The total costs for adult stem 
cell donation incurred over the time period 1997–2009 
amounted to sums of between 4.2 and 5.8 billion USD in 
the health-system-based approach. Prices per procured 
product (division by cumulated donations) led to a unit 
price of between 47,638 and 65,681 USD per product 
Table 7 Health system-wide cost calculation (cord blood) using various approaches
Cum. PPU (USD) Total (USD) PPP (USD) Total (USD) PPP2 (USD)
Sirchia “A”
CBU available 537,000 11,602 6,230,274,000 6,230,274,000
CBU provided 21,387 27,579 589,832,073 589,832,073
Total 3.98% 6,820,106,073 318,890 5,640,441,927 263,732
Sirchia “B”
CBU available 537,000 46,408 24,921,096,000 24,921,096,000
CBU provided 21,387 27,579 589,832,073 589,832,073
Total 3.98% 25,510,928,073 1,192,824 24,331,263,927 1,137,666
Howard “A”
CBU available 537,000 31,107 16,704,459,000 16,704,459,000
CBU provided 21,387 27,579 589,832,073 589,832,073
Total 3.98% 17,294,291,073 808,636 16,114,626,927 753,478
Howard “B”
CBU available 537,000 29,568 15,878,016,000 15,878,016,000
CBU provided 21,387 27,579 589,832,073 589,832,073
Total 3.98% 16,467,848,073 769,993 15,288,183,927 714,835
Notes: Calculations based on the publications of Sirchia et al7 and Howard et al.8 For each publication, an optimistic approach (“A”) and a realistic approach (“B”) was 
defined.
Abbreviations: Cum, cumulative; PPU, price-per-unit; PPP, price-per-product (system based approach); PPP2, price-per-product (institution-based approach).
Table 8 Health system-wide cost calculation (unrelated adult stem cell products) using various approaches
Cum. Price (USD) Total (USD) PPP (USD) Total (USD) PPP2 (USD)
Kollman
Donors 16,400,000 141 2,312,400,000 2,312,400,000
Total donations 88,422 21,486 1,899,835,092 1,899,835,092
Total 0.54% 4,212,235,092 47,638 412,564,908 4,666
Kollman “B”
Donors 16,400,000 200 3,280,000,000 3,280,000,000
Total donations 88,422 21,486 1,899,835,092 1,899,835,092
Total 0.54% 5,179,835,092 58,581 1,380,164,908 15,609
Kollman/Smith “B”
Donors 16,400,000 200 3,280,000,000 3,280,000,000
Total donations (Products) 88,422 7,100 627,796,200 627,796,200
Total donations (Fees) 88,422 21,486 1,899,835,092 1,899,835,092
Total 0.54% 5,807,631,292 65,681 2,007,961,108 22,709
Notes: Calculations based on the publications of Kollman et al9 and Smith et al.11 For each publication, an optimistic approach (“A”) and a realistic approach (“B”) was 
defined.
Abbreviations: Cum, cumulative; PPP, price-per-product (system based approach); PPP2, price-per-product (institution-based approach).ClinicoEconomics and Outcomes Research
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(for BM and PBSC respectively). Although we regard the 
institution-based approach (“PPP2”) as less relevant than 
the health system-based approach, the price differential 
between cord blood and adult stem cell product remained 
in roughly the same range.
Discussion
It was clear to the author that there had to be significant dif-
ferences in cost between CB and BM/PBSC, due to the fact 
that the vast majority of stored CBUs has not been used for 
purposes of transplantation. Nevertheless, the extent of these 
differences has been unexpected. In each of the models on 
which the different comparisons have been based, the price 
differential of CB to PM/PBSC was a multiple between the 
former and the latter. Taking into account the global health 
systemwide cost totals, differences amounting to a height of 
1–2 × 1010 USD can be postulated. These are magnitudes which 
should justify further regard and discussion at a policy level.
Conclusion
We are aware that further calculations have to be made in 
order to arrive at more precise unit costs. Yet we do think 
that the striking differences of true (health system-related) 
unit costs between cord blood and adult stem cell products 
merit further analysis. With regard to cord blood, a further 
increase of worldwide inventories should be thoroughly 
weighed against alternative approaches (eg, further increase 
of adult donor registries respectively enhancing qualitative 
performance of adult registries through improved availabili-
ties). Notwithstanding these points, serious efforts should 
be undertaken in order to reduce costs in the entire business 
process of cord blood banking (harvesting, processing, 
storage). The consequences of a continuation of the current 
system could otherwise be regarded as being prohibitively 
expensive to deciders in our health systems.
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